The high failure rate in Phase Ⅲ clinical trials has raised more and more attention on opti-mizing the drug development design as well as a better utilization of data from early trial/study.One of the potential statistical remedies to this problem is the concept of assurance,which assumes that the treatment effect follows a prior distribution based on existing knowledge.